CVS Health (CVS) Gets a Hold Rating from Oppenheimer


In a report released today, Michael Wiederhorn from Oppenheimer maintained a Hold rating on CVS Health (CVS). The company’s shares closed last Monday at $73.85, close to its 52-week high of $77.03.

According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 17.2% and a 71.9% success rate. Wiederhorn covers the Services sector, focusing on stocks such as The Ensign Group, Addus Homecare, and UnitedHealth.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $87.71 average price target.

See today’s analyst top recommended stocks >>

Based on CVS Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $64.81 billion and net profit of $1.53 billion. In comparison, last year the company earned revenue of $54.42 billion and had a GAAP net loss of $419 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts